OncoMatch/Clinical Trials/NCT05195710
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
Is NCT05195710 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Yttrium-90 (Y-90) resin microspheres for metastases.
Treatment: Yttrium-90 (Y-90) resin microspheres — A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Metastatic disease required
Prior therapy
Must have received: cytotoxic chemotherapy
Received at least four cycles (or two months) of chemotherapy
Lab requirements
Blood counts
Platelet count ≥100,000/µL
Liver function
Starting total bilirubin ≤1.3 mg/dL (except if patient has Gilbert's Disease); no portal hypertension and/or cirrhosis; albumin ≥3.5 g/dl
Portal hypertension and/or cirrhosis; Starting total bilirubin >1.3 mg/dL (except if patient has Gilbert's Disease); Platelet count <100,000/µL; Albumin <3.5 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05195710 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received cytotoxic chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify